Why These Are Not the Same Thing There is growing confusion around kratom because some people claim that since mitragynine can convert into 7-hydroxymitragynine (7-OH) in the human liver, natural kratom is “basically the same” as commercial 7-OH products. That claim is scientifically incorrect. Here is the clear, factual difference. 1. Mitragynine and 7-OH Are Not Equivalent in the Body Natural kratom leaf contains mitragynine as its primary alkaloid. When consumed orally, a very small fraction of mitragynine is metabolized in the liver into 7-hydroxymitragynine. - This conversion is trace-level - It represents well under 1% of the mitragynine consumed - Most estimates place it around 0.01%–0.1% In practical terms, this means the body produces micrograms, not milligrams, of 7-OH. Commercial 7-OH products deliver milligram-level doses directly, bypassing the body’s natural metabolic limits. 2. The Liver Is a Limiting System, Not a Production Factory The human liver does not efficiently convert mitragynine into 7-OH. - 7-OH is a minor metabolic byproduct, not a primary outcome - Most mitragynine is converted into other metabolites, not 7-OH - First-pass metabolism naturally caps exposure This is a built-in biological safeguard. Commercial 7-OH products remove that safeguard entirely. 3. Potency Does Not Equal Exposure Yes, 7-OH is more potent per milligram than mitragynine. That fact is often misused. What matters is how much actually reaches the bloodstream. Natural kratom: - Slow oral absorption - Low peak concentrations - Mixed alkaloid profile - Trace endogenous 7-OH formation Commercial 7-OH products: - High potency - High concentration - Rapid spikes - No alkaloid balance - No metabolic ceiling These are fundamentally different pharmacological profiles. 4. A Simple Real-World Comparison A typical serving of plain-leaf kratom may contain 30–50 mg of mitragynine Endogenous 7-OH formation from that amount is measured in micrograms A single commercial 7-OH tablet may contain 10–20 mg of isolated 7-OH

5th Scientific Kratom Symposium (Feb 17–20, 2026, University of Florida) Published by: Frontiers Media DOI: 10.3389/978-2-8325-6564-3 Note: Abstract collection only (not peer-reviewed by Frontiers). Executive-Level Summary The 5th Scientific Kratom Symposium brought together leading researchers across pharmacology, toxicology, clinical medicine, botany, genomics, addiction science, and public health. The central theme was clear: Plain leaf kratom, its primary alkaloid mitragynine, and emerging semi-synthetic derivatives (especially 7-hydroxymitragynine) are not the same category of product and should not be treated as such scientifically or regulatorily. Below is a structured breakdown of the key scientific takeaways. 1. Brain Pharmacology & Mechanisms Blood–Brain Barrier Transport Mitragynine crosses the blood–brain barrier via organic anion transporters (OATs) and is restricted by P-glycoprotein efflux. Implication:Brain entry is slower and regulated compared to fast-penetrating opioids. This supports a lower addiction liability profile relative to classical opioids. μ-Opioid Receptor Signaling Isolated kratom alkaloids showed: - G-protein–biased signaling - Minimal or no β-arrestin recruitment Translation:This signaling bias may help explain why kratom alkaloids do not behave identically to full opioid agonists like morphine. 2. Toxicology & Safety Differentiation Comparative Lethality Study (Rats) Tolerance levels: - Kratom leaf powder: Well tolerated at very high doses - Kratom leaf extract: Moderate toxicity - 7-hydroxymitragynine isolate: Significantly higher acute toxicity

1. Safety Classification - Safety Class 2b, 2c - Interaction Class B This entry specifically focuses on traditional kratom leaf preparations (chewed leaf, tea, decoction), not highly concentrated extracts or enhanced products. 2. Traditional Use Context - Indigenous to Southeast Asia. - Leaves traditionally: - Commonly used similarly to coffee by laborers for endurance and stress resilience. - Typically consumed 1–4 servings per day in traditional settings. Important distinction: The handbook differentiates plain leaf from modern concentrated extracts or alkaloid-enhanced products, which fall outside the scope of this safety review. 3. Alkaloid Composition Kratom leaf contains: - 0.5–3% total alkaloids by dry weight. - Primary alkaloid: - Other notable alkaloids: 7-Hydroxymitragynine (7-OH): - Present naturally at trace levels (0.00–0.06% w/w) in leaf. - Environmental factors (light, soil, water) influence alkaloid variability. The “red/green/white vein” marketing claims: - Current analytical data show no significant cross-strain alkaloid differences. - Reported effect differences may be driven more by marketing than chemistry. 4. Standard Serving Range Traditional dried leaf intake: - ~0.2–4.3 grams per serving (based on leaf weight) - U.S. surveys: - Typical mitragynine exposure: 5. Dependency & Withdrawal Key conclusion: dose- and duration-dependent. At moderate intake: - ≤5 grams per serving: negative effects uncommon - <4 glasses of tea/day: withdrawal unlikely Reported withdrawal symptoms (when present): - Muscle aches - Insomnia - Runny nose - Anxiety - Irritability - Mood disturbance Severity is generally described as milder than classical opioid withdrawal in the surveyed literature. 6. Adverse Events Mild to Moderate Effects (more common at higher doses): - Nausea - Dizziness - Fatigue - Headache - Insomnia - Jitteriness Higher-Dose or Non-Traditional Products:

For years, kratom has existed in a strange regulatory limbo. Widely used, heavily debated, and often misunderstood. Critics have relied on anecdotes and worst-case assumptions, while consumers and researchers have asked for something far more boring and far more powerful: real data. Now we have it. A newly published randomized clinical trial evaluating dried kratom leaf powder in healthy adults delivers the most rigorous safety data to date. The findings are measured, clinical, and inconvenient for sensational headlines. Kratom talk is usually loud, political, and emotional. This is the opposite: a controlled human study, published January 5, 2026 in Therapeutic Drug Monitoring, testing a well-characterized dried kratom leaf powder in healthy adult volunteers, with placebo controls, dose escalation, and close medical monitoring. This post breaks down what the study did, what participants experienced, what the labs showed (especially liver enzymes), and what the authors concluded about abuse potential and withdrawal. Then we translate it into practical takeaways for real-world “plain leaf kratom” consumers. This post also discusses the broader implications for kratom studies. New peer-reviewed research adds to a substantial body of scientific evidence highlighting the safety of natural kratom leaf. What This Study Set Out to Answer The study was designed to answer a basic but critical question: Is traditionally prepared, plain kratom leaf powder safe and tolerable when used by healthy adults under controlled conditions?

Kratom talk is usually loud, political, and emotional. This is the opposite: a controlled human study, published January 5, 2026 in Therapeutic Drug Monitoring, testing a well-characterized dried kratom leaf powder in healthy adult volunteers, with placebo controls, dose escalation, and close medical monitoring. This post breaks down what the study did, what participants experienced, what the labs showed (especially liver enzymes), and what the authors concluded about abuse potential and withdrawal. Then we translate it into practical takeaways for real-world “plain leaf kratom” consumers. What Study Was This? This is the Single Ascending Doses of Kratom in Healthy Nondependent Adults With Opioid Experience Study done by the FDA. Design: randomized, double-blind, placebo-controlled, dose-escalation trial in 116 healthy adults (49 active, 67 placebo).Product: MitraLeaf, an encapsulated dried Mitragyna speciosa leaf powder with defined mitragynine content and very low 7-OH listed on the Certificate of Analysis. Dosing plan: - Single dose (SD): one of four mitragynine dose levels delivered via leaf powder. - Multiple dose (MD): the same people then took 15 once-daily doses at their assigned level. - Follow-up: monitoring continued for 23 days after the last dose. The Big Headline Result No serious adverse events and no deaths occurred in the active kratom group or placebo group. The authors concluded the dried leaf powder was “safe and well tolerated” at the tested doses, with no evidence of meaningful abuse potential or withdrawal during the study window. That is not a “kratom is harmless forever” card. It is a strong data point: controlled conditions, known product, known doses, careful monitoring. Read More